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Abstract
Background: Human embryonic stem cells (hESCs) may provide an invaluable resource for regenerative medicine. To move
hESCs towards the clinic it is important that cells with therapeutic potential be reproducibly generated under completely
defined conditions.
Methodology/Principal Findings: Here we report a four-step scalable process that is readily transferable to a Good
Manufacture Practice (GMP) facility for the production of functional dopaminergic neurons from hESCs for potential clinical
uses. We show that each of the steps (propagation of ESCRgeneration of neural stem cells (NSC)Rinduction of
dopaminergic precursorsRmaturation of dopaminergic neurons) could utilize xeno-free defined media and substrate, and
that cells could be stored at intermediate stages in the process without losing their functional ability. Neurons generated by
this process expressed midbrain and A9 dopaminergic markers and could be transplanted at an appropriate time point in
development to survive after transplant.
Conclusions/Significance: hESCs and NSCs can be maintained in xeno-free defined media for a prolonged period of time
while retaining their ability to differentiate into authentic dopaminergic neurons. Our defined medium system provides a
path to a scalable GMP-applicable process of generation of dopaminergic neurons from hESCs for therapeutic applications,
and a ready source of large numbers of neurons for potential screening applications.
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Introduction
Pluripotent human embryonic stem cells (hESCs) have the
capacity to differentiate into all of the somatic cell types and
therefore hold great promise for regenerative medicine. One key
issue that needs to be addressed in guiding hESC technology from
‘‘bench’’ toward ‘‘bedside’’ is developing defined cell culture
systems for culture of hESCs, and differentiation of such cells into
therapeutically relevant cells using clinically compliant systems.
Early hESC culture systems typically include the use of mouse
embryonic fibroblast (MEF) feeders or medium conditioned on
MEFs in the presence of serum or serum substitutes such as
knockout serum replacement [1–3]. Human feeders and serum
have also been used for hESC culture [4], however, the use of
serum or serum replacement which contains undefined xenogenic
factors in such cultures is still an issue for potential clinical
applications. Recent advances in the identification of multiple
factors that play a role in sustaining pluripotency have led to the
report of several defined medium systems for hESC culture and
derivation [5–9]. These defined media are based upon the use of
FGF2 in combination with TGFb/nodal/activin signaling mole-
cules, IGF1R or N2/B27 supplements, and do not include serum
or serum replacement. Two such defined media (TeSR1 from
Stem Cell Technology and StemPro from Invitrogen) are currently
commercially available.
Despite this progress in the development of defined medium
systems for culturing hESCs, little is known about whether hESCs
derived in defined media or cultured in defined media for an
extended period can differentiate into functional cells of therapeutic
relevance under xeno-free defined conditions. Indeed, few defined
culture systems have been described for lineage-specific differenti-
ation, despite the fact that cells with potential therapeutic uses
including neurons, cardiomyocytes and insulin-producing beta cells
have been successfully generated from hESCs. Most of the current
protocols include the step of embryoid body (EB) formation with
serumorserumreplacement,whichintroduces componentsthatare
not chemically defined. Thus, further efforts arewarranted to define
robust culture systems for lineage-specific differentiation of hESCs
adapted to or derived from defined medium into various
therapeutically relevant somatic cells.
Of particular interest are midbrain dopaminergic neurons, the
population of neurons selectively lost in Parkinson’s disease (PD).
Since the motor symptoms of PD are a consequence of focal
damage to dopaminergic neurons of substantia nigra, it has been
widely suggested that implantation of a relatively small number of
dopaminergic neurons may restore functionality in PD patients. In
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dopaminergic neurons derived from fetal and/or embryonic cells
survive, reinnervate appropriate targets, and function in vivo in
rodent and non-human primate PD models [10–15]. Proof of
principle for cell replacement therapy in PD has also been
achieved in several clinical trials by using fetal derived dopami-
nergic neurons [16–19]. Contemporary work has shown that
authentic dopaminergic neurons can be generated from hESCs,
which may provide an unlimited source of cells for transplantation,
and grafts of these cells can release dopamine and ameliorate
behavioral deficits in rodent PD models [20–22]. We believe the
time is right for the development of scalable protocols for
generating dopaminergic neurons from hESCs using completely
defined, xeno-free components. This approach will facilitate
subsequent adaptation of protocols to Good Manufacturing
Practice (GMP) standards which is a pre-requisite for progression
towards clinical trials.
In pursuing this goal, we have developed a GMP-compliant
scalable process of generating neural stem cells (NSCs) and further
differentiate them into dopaminergic neurons in defined conditions
from hESCs adapted to a definedmedium. We showthat functional
dopaminergic neurons can be generated under completely defined
conditions from hESCs adapted to a defined medium system. We
believe our system not only provides a platform for producing
therapeutic cells from hESCs for PD patients, but also a generalized
plan for how hESC culture and lineage-specific differentiation need
to be developed for treatment of other degenerative disorders,
including spinal cord injury and type I diabetes.
Materials and Methods
Cell culture
hESC line I6 at passage 42 was adopted to serum-free StemPro
hESC SFM defined medium and maintained on culture dishes
coated with xeno-free CellStart or Geltrex (All from Invitrogen;
Carlsbad, CA). The medium comprises of DMEM/F12 with
GlutaMax, BSA 1.8%, b-Mercaptoethanol 0.1 mM, 16StemPro
protein cocktail (All from Invitrogen) and 8 ng/ml of basic
fibroblast growth factor (FGF2, Sigma). Cells were split every 4–6
days using a cell scraper.
Generation and prolonged culture of NSCs
To derive NSCs, hESC colonies were harvested using a scraper
with care taken to avoid high colony fragmentation. Colonies were
cultured in suspension as EBs on Petri dishes with agitation for 8
days in StemPro defined media minus FGF2. EBs were then
cultured for additional 2–3 days in suspension in neural induction
media containing DMEM/F12 with Glutamax, 16NEAA, 16N2
and FGF2 (20 ng/ml) prior to attachment on cell culture plates
coated with CellStart. Numerous neural rosettes were formed 2–3
days after adherent culture. To obtain a pure population of NSCs,
rosettes were manually isolated using stretched glass Pasteur pipette
and placed in fresh culture dishes. The rosettes were then
dissociated into single cells using accutase and replated onto culture
dishes to obtain a homogeneous population of NSCs. The NSCs
population was expanded in Neurobasal media containing
16NEAA, 16L-Glutamine (2 mM), 16B27, LIF, FGF2 20 ng/ml.
To confirm that NSCs can differentiate into astrocytes, NSCs
were cultured in DMEM/F12 medium supplemented with
16NEAA, L-Glutamine (2 mM), 16N2 and 16B27 for two
weeks and processed for immunostaining. To initiate oligoden-
drocyte differentiation, NSCs were cultured in medium containing
DMEM/F12, 16NEAA, 16L-Glutamine (2 mM), 16N2, 16B27,
Shh (200 ng/ml, R&D Systems) and retinoic acid (RA, 2 mM) for
10 days, and then with T3 (30 ng/ml, R&D Systems) and PDGFa
(10 ng/ml, R&D Systems) but without Shh and RA for an
additional 2 weeks.
Dopaminergic differentiation of NSCs
Dopaminergic differentiation was obtained by culturing NSCs
in medium conditioned on PA6 cells (PA6-CM) [23] for 3–6
weeks, or in xeno-free defined media for 4–5 weeks on culture
dishes or glass cover slips coated with Poly-L-ornithine (20 ug/ml)
and laminin (10 ug/ml). Dopaminergic differentiation in defined
media was initiated by culturing NSCs for 10 days in Neurobasal
medium supplemented with 16NEAA, 16L-Glutamine (2 mM),
16B27 (Gibco), Shh (200 ng/ml, R&D Systems) and FGF8 (50–
100 ng/ml, R&D Systems). Shh and FGF8 were then withdrawn
and replaced with BDNF (20 ng/ml, R&D Systems) and GDNF
(20 ng/ml, R&D Systems), TGF-b3( 1mM, R&D Systems) and
dcAMP (1 mM, Sigma) for 10–25 days.
Immunocytochemistry
Immunocytochemistry and staining procedures were as de-
scribed previously [24]. Briefly, hESCs at different stages of
dopaminergic differentiation were fixed with 2% paraformalde-
hyde for half an hour. Fixed cells were blocked in blocking buffer
(10% goat serum, 1% BSA, 0.1% Triton X-100) for 1 hour
followed by incubation with the primary antibody at 4uC
overnight in 8% goat serum, 1% BSA, 0.1% Triton X-100.
Appropriately coupled secondary antibodies (Molecular Probes)
were used for single and double labeling. All secondary antibodies
were tested for cross reactivity and non-specific immunoreactivity.
The following primary antibodies were used: Oct4 (ab19857
AbCam) 1:1000; b-Tubulin isotype III clone SDL.3D10 (T8660
Sigma) 1:500; GalC (MAB342 Millipore) 1:50; GFAP (M0761
Chemicon) 1:50; Nestin (611658 BD Transduction laboratories)
1:500; Sox1 (AB5768 Chemicon) 1:200, TH (Pel-Freeze P40101)
1:500, TH clone TH-16 (T2928 Sigma) 1:1000; Lmx1a (a kind gift
from Dr. Michael German, UCSF) 1:1500, Girk2 (AB5200
Chemicon) 1:250; Vmat2 (PPS089 R&D) 1:1000, GABA
(ab8891 Abcam) 1:500, L-Glutamate (ab8889 Abcam) 1:500,
DBH (AB1585 Chemicon) 1:1000, HB9 (81.5C10 DSHB) 1:50,
and as secondary antibodies: Alexa Fluor 488 Goat Anti-Mouse,
Alexa Fluor 594 Goat Anti-Mouse, Alexa Fluor 488 Goat Anti-
Rabbit, Alexa Fluor 594 Goat Anti-Rabbit. Hoechst 33342
(Molecular Probes H3570) 1:1000 was used for nuclei identifica-
tion. Images were captured on a Nikon fluorescence microscope.
The quantification of TH
+ cells in culture was performed by
analyzing fluorescent images using Photoshop on a minimum of
5000 cells of at least 10 randomly chosen fields derived from 3 or
more independent experiments. The number of Hoechst labeled
nuclei on each image was referred as total cell number (100%).
Gene expression and PCR analysis
RNAs isolated from NSCs and dopaminergic populations were
hybridized to Illumina HumanRef-8 BeadChip (Illumina, Inc,
performed by Microarray core facility at the Burnham Institute for
Medical Research). The Illumina array data were normalized by
the quantile method, and then transformed log2 ratio values for a
zero mean for expression values of each gene across all samples.
The bioinformatics and statistical analyses were conducted by
using R and the bioconductor package (www.bioconductor.org).
cDNA was synthesized by using a reverse transcription kit
SuperScript III First-Strand Synthesis System for RT-PCR
(Invitrogen) according to the manufacturer’s recommendations.
Real-time PCR was used to quantify the levels of mRNA
expression of 10 genes in NSC and day 16 and 31 dopaminergic
Xeno-Free Dopaminergic Neurons
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instrument according to the manufacturer’s instructions. All qRT-
PCR primer sequences are shown in supplementary Table S1.
Transplantation of hESC-derived dopaminergic neurons
into rat brains and histological analysis
Adult female Sprague-Dawley rats (200–230 g) were purchased
from Charles River Laboratories (Wilmington, MA, USA). Four
rats were injected with day 20 (after the NSC stage) hESC-derived
neuronal populations (approximately 500,000 cells in 5 ml of cell
preparation medium) or vehicle with a Hamilton syringe into the
striatum (20.3 mm anterior to bregma, 3.0 mm lateral to midline,
and 5.0 mm beneath dura). Cyclosporine A (10 mg/kg; Novartis
Pharmaceuticals) was intraperitoneally injected 24 hours before
transplantation and every day afterwards until the rats were
sacrificed. Experimental protocols were in accordance with the
National Institutes of Health Guidelines for Use of Live Animals
and were approved by the Animal Care and Use Committee at the
Buck Institute. Rats were perfused with phosphate-buffered saline
(PBS) followed by 4% paraformaldehyde.
For histological analysis, brains were removed and immersion-
fixed overnight at room temperature. Brains werethen dehydrated in
graded ethanols, cleared in xylene, and paraffin-embedded [25].
Seven mm-thick serial coronal sections were cut and mounted on glass
slides, which were dried overnight at 42uC. Sections were
deparaffinized, rehydrated through a graded series of ethanols, and
washed in water. For immunostaining [26], sections were incubated
with blocking solution (2% horse serum, 1% bovine serum albumin,
and 0.1% Triton X-100 in phosphate-buffered saline, pH 7.5) and
then with primary antibodies at 4uC overnight followed by secondary
antibodies in blocking solution at room temperature for 2 h. The
primary antibodies used were rabbit anti-TH polyclonal antibody
(Chemicon, 1:500) and mouse polyclonal anti-humannuclear antigen
(Chemicon, 1:300). The secondary antibodies were rhodamine-
conjugated rat-absorbed donkey anti-rabbit IgG (Jackson ImmunoR-
esearch; 1:200) and fluorescein isothiocyanate-conjugated pig anti-
mouse IgG (Vector Laboratories; 1:200). Nuclei were counterstained
with 49,6-diamidino-2-phenylindole (DAPI) using proLong Gold
anti-fade reagent (Invitrogen). To quantitatively analyze double
labeled neurons in the striatum, fluorescence signals were detected
with an LSM 510 NLO Confocal Scanning System mounted on an
Axiovert 200 inverted microscope (Carl Zeiss Ltd.) equipped with a
two-photon Chameleon laser (Coherent Inc.). Three-color images
were scanned using Argon and 543 HeNe lasers. IMARIS (Bitplane
AG.) imaging software was used for three-dimensional image
reconstruction. Images were acquired using LSM 510 Imaging
Software(CarlZeissLtd.)asdescribedpreviously[27].Thespecificity
of each label was first verified using single-channel scans that were
then merged into multiple-channel views. Neurons were considered
double-labeled if co-labeling with relevant morphology was seen
throughout the extent of the nucleus for nuclear markers or if a
cytoplasmic marker surrounds a nuclear marker when viewed in x-y
cross section as well as in x-z and y-z cross-sections produced by
orthogonal reconstructions from z-stacks taken at 4006magnifica-
tion. Human antigen single-labeled neurons and neurons double
labeled for TH and human antigen were recorded in every seventh
section per animal (n=3). The area of each transplanted region was
simultaneously determined for each of the scored sections.
Transplantation into the 6-hydroxydopamine rats and
behavior analysis
Thirty rats were anesthetized and 16 mg of 6-hydroxydopamine
(6-OHDA) (Sigma-Aldrich) were stereotaxically injected at a
concentration of 4 mg/ml (in 0.2 mg/ml ascorbate in saline) at
one site in the MFB [stereotaxic coordinates: anteroposterior (AP),
24.4 mm; mediolateral (ML), 21.2 mm; dorsoventral (DV),
27.8 mm] using a Hamilton syringe. The toxin was injected at
a rate of 1 ml/min. To ensure complete lesion of the nigrostriatal
DA pathway, the animals were screened by amphetamine-induced
rotation at a dose of 2.5 mg/kg. Only animals (26) that exhibited a
mean ipsilateral rotation score of seven or more complete body
turns per minute were included in the study.
For rational behavior analysis the animals were given 2.5 mg/
kg D-amphetamine intraperitoneally and their rotational behavior
was monitored over a 90 min period using the TSE rotameter
system (Bad Homburg, Germany). Rotation toward the lesion
(ipsilateral) was scored as positive and net rotational asymmetry
score were expressed as full body turns per minute.
Results
NSCs can be generated from hESCs adapted to a serum-
free defined condition and a defined substrate
We have previously reported the culture of hESCs in a serum-
free, completely chemically defined medium [28] and wished to
test whether cells adapted to such defined conditions can give rise
to NSCs. We employed two hESC lines (I6 and W10) and, since
the results were similar, only the results from one of the lines (I6)
are reported here. I6 cells were continuously cultured in this
defined medium (StemPro ESC defined medium) for 6 months on
a defined substrate (CellStart). As seen in Fig. 1A–B, hESCs
cultured in defined medium and substrate showed typical
undifferentiated morphology without differentiated cells surround-
ing the colonies, and expressed the pluripotency marker Oct4. No
karyotypical abnormality was detected in cultures after over 25
passages (data not shown).
To generate NSCs, ESC colonies grown in defined medium
were detached and cultured in suspension as EBs in ESC defined
medium without FGF2 for 8 days. EBs were directed towards
neural lineages by the addition of FGF2 and allowed to attach in
adherent cultures in a defined serum-free medium. After 2–3 days
of attachment, numerous neural tube-like rosette structures were
formed in the center of the ESC colonies (Fig. 1C), which were
immuno-positive for nestin (Fig. 1D). The rosettes were manually
dissected and expanded in NSC proliferation medium on defined
substrate (Fig. 1E). Morphologically, these cells were homogenous
and uniformly expressing nestin and Sox1, a transcription factor
expressing in early neuroepithelial cells (Fig. 1F). Few cells (less
than 1%) expressed b-III tubulin and no cells were positive for
GFAP or O4 (data not shown). We noted that several radial glia
markers such as Glast, Vim and Blbp were upregulated in our
NSC population (Expression level measured by intensity for Glast,
Vim and Blbp are 433, 16719 and 1273, respectively) compared to
undifferentiated ESCs (Expression level measured by intensity for
Glast, Vim and Blbp are 209, 10065 and 200, respectively) by
global gene expression using Illumina array, consistent with the
observation by Nat et al. that radial glia markers were expressed in
ESC-derived NSCs [29]. These results indicate that NSCs can be
generated in defined conditions from hESCs adapted to defined
conditions.
Prolonged culture of NSCs in defined conditions does
not diminish their ability to differentiate
To test whether NSCs could be propagated in a defined medium
for a prolonged period and retain the capacity to differentiate into
neurons and glia, we continuously passaged the cells in the defined
medium (NSC medium) on defined substrate for over 2 months. As
Xeno-Free Dopaminergic Neurons
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passages expressed Sox1 and nestin, and differentiated into b-III-
tubulin
+ neurons, GFAP
+ astrocytes and GalC
+ oligodendrocytes in
conditions promoting differentiation (Fig. 2B–C). In addition, these
cells could be frozen and thawed with greater than 95% viability
and without losingthe ability to differentiateintoneurons (including
dopaminergic neurons) and glia.
NSCs cultured for prolonged periods retain their ability
to differentiate into dopaminergic neurons upon
exposure to PA6-CM or in a xeno-free defined medium
Our laboratory has reported dopaminergic inducing activity of
medium conditioned on stromal cell line PA6 (PA6-CM) and shown
that exposure to PA6-CM at a defined time period (NSC stage) was
sufficient for a dopaminergic fate [23]. We therefore tested whether
NSCs grown to passages 15–25 in defined conditions could
differentiate into dopaminergic neurons in PA6-CM. As shown in
Fig. 3, dopaminergic neuronal induction by PA6-CM was efficient,
as numerous b-III tubulin
+ neurons (A) and TH
+ cells (B) were
present in the cultures after 3 weeks of differentiation. The average
percentage of TH
+ neurons was 3565% at day 20.
To further test if cells generated under these conditions were
authentic midbrain dopaminergic neurons of the A9 type, we first
examined the expression of additional midbrain dopaminergic
markers in our cultures by immunocytochemistry. After 5 weeks of
differentiation, a high percentage of the cells expressed Lmx1a, a
transcription factor involved in dopaminergic development. Many
Figure 1. Generation of NSCs from hESCs adapted to defined medium. hESC line I6 at passage 42 was adapted to a chemically defined
medium StemPro. (A–B) Morphology (A) and expression of the pluripotent marker Oct4 (B) in hESCs that were cultured in StemPro for 28 passages.
(C–F) Generation of NSCs in defined conditions. Nestin
+ neural tube-like rosette structures were formed in the center of the ESC colonies after 12–14
days of differentiation (C–D). A monolayer of homogeneous NSCs expressed Sox1 and nestin (E–F).
doi:10.1371/journal.pone.0006233.g001
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+ neurons co-expressed Lmx1a (Fig. 3C). VMAT was also co-
expressed in the majority of TH
+ neurons (Fig. 3D). Importantly,
Girk2, a marker of nigral neurons, was co-expressed in many TH
+
neurons (Fig. 3E). The expression of a few other neuronal markers
in our culture was also analyzed by immunostaining. We did not
see DBH-positive cells in our culture and found a very small
percentage of the cells (,1%) expressed GABA (Supplementary
Figure S1). No glutamate or HB9 immunoreactive cells were
found in the culture.
We then used real time PCR to examine the expression of a
panel of 10 markers (En1, Otx2, Msx1, Nurr1, Lmx1b, AADC,
Aldh1a, VMAT, DAT and Girk2) during dopaminergic differen-
tiation (NSCs, day 16 and day 31). As seen in Fig. 3F, many of
these genes (En1, Msx1, Nurr1, Lmx1b, AADC, VMAT, DAT
and Girk2) were differentially upregulated in both day 16 and day
31 dopaminergic populations compared to the NSC population.
Finally we performed a large-scale microarray for gene
expression profiling of the day 32 dopaminergic population. As
summarized in Table 1, many midbrain and dopaminergic
neuronal markers such as EN1, Pax2, Otx2, Msx1, Lmx1a,
Ngn2 and Nurr1, transcription factors that were believed to be
important in regulating dopaminergic differentiation, were
detected in the day 32 dopaminergic population. These results
indicate that our culture conditions can efficiently generate
authentic A9 type neurons.
Since PA6 is a mouse stromal cell line and PA6-CM is not
defined, in a separate set of experiments we identified a candidate
set of factors that may substitute for PA6-CM in cultures
(unpublished data). Given the present results, we tested whether
the effects of PA6-CM could be mimicked with a combination of
growth factors in a defined medium base. Our gene expression
data and preliminary experiments indicated that Shh and FGF8
may substitute for PA6-CM as a source of dopaminergic inducing
activity (Step 3: NSCRdopaminergic precursor) and that TGFb,
GDNF and BDNF may mimic the effect of dopaminergic neuron
maturation and survival (Step 4: dopaminergic precursorRdopa-
minergic neuron). To test this, NSCs were exposed to Shh and
FGF8 in a defined medium (NSC defined medium minus FGF2
with the addition of Shh and FGF8) for 10 days followed by 18
days of culture in the presence of TGFb, GDNF and BDNF
without Shh and FGF8, in the same basal serum-free defined
medium (Fig. 4A). Under these conditions, approximately 25% of
the cells expressed TH (Fig. 4B). The efficiency of this
dopaminergic differentiation is comparable to that observed with
exposure to PA6-CM for 3 weeks. These results indicate that Shh
and FGF8 could replace PA6-CM in the step of dopaminergic
induction from the NSC stage and that BDNF, GDNF and TGFb
were sufficient to maintain the differentiated population.
Survival of dopaminergic neurons in vivo
To examine the functional properties of dopaminergic neurons
derived from ESCs/NSCs cultured in defined medium, we
transplanted cells that had been differentiated for 20 days (after the
NSC stage) into the striatum of rats. Immunohistochemical analysis
was performed 2 and 7 weeks after grafting and donor cells of human
origin (positive for human nuclear antigen) were found in all brains
throughout the graft sites (Fig. 5A–D). A small number of TH
+
human cells were identified in the brain at the graft site 2 weeks post
Figure 2. NSCs cultured in xeno-free defined medium for a prolonged period remain to be multipotent. (A) NSCs propagated in defined
conditions for 15 passages retained NSC identity as evident by expressing Sox1 and nestin. (B–C) NSCs can be frozen and thawed and maintained the
capacity to differentiate into neurons (B), oligodendrocytes (C) and astrocytes (D).
doi:10.1371/journal.pone.0006233.g002
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+ human neurons were
increased in brains 7 weeks after grafting (Fig. 5E–H). These results
indicate that dopaminergic neurons generated from ESCs/NSCs
cultured in defined medium couldsurvive and integrate into the brain
in vivo for at least 7 weeks, the duration of the present study. At 7
weeks post-transplantation, histological analyses showed that
2,5796581 cells/mm
3 were TH-positive neurons among the
110,193619,746 cells/mm
3 in these grafts.
Figure 3. NSCs from prolonged culture in defined conditions can be efficiently differentiated into midbrain dopaminergic neurons.
(A–E) Efficient differentiation into midbrain dopaminergic neurons by PA6-CM as shown by immunocytochemistry. The majority of the cells expressed
b-III-tubulin and TH after 4 weeks of differentiation in PA6-CM (A–B). Co-expression of midbrain and A9 markers in TH
+ dopaminergic neurons: Lmx1a
(C), VMAT (D) and Girk2 (E). (F) Differential expression of dopaminergic markers in several stages of differentiation (NSC, dopaminergic precursors and
dopaminergic neurons) by quantitative PCR. All the examined markers were up-regulated in dopaminergic populations compared to NSCs.
doi:10.1371/journal.pone.0006233.g003
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our culture conditions contained functional dopaminergic neu-
rons, we transplanted the cells (20 days after the NSC stage) into
eighteen 6-OHDA rats and showed that they can ameliorate
behavioral deficits in PD rats. As seen in Fig. 5M, eight control rats
that were transplanted with medium showed no attenuation of
rotary behavior over the course of the experiment, whereas rats
that were transplanted with grafts demonstrated significant
rotational improvement at 12 and 16 weeks after transplantation
(p,0.05). Human antigen-immunopositive cells co-expressing TH
were found in all brains throughout the graft sites at 8 weeks
following the transplantation (Fig. 5I–L).
Completely serum- and xeno-free defined culturing of
hESCs and NSCs
Examining our protocols we noted that while our simplified
protocols for hESC culture, deriving NSCs, and inducing and
maintaining dopaminergic neurons worked well, both the ESC
medium and NSC medium used contained one xeno component,
BSA. We therefore tested if cells could be grown in a completely
humanized base medium with hKSR and the growth factors
(Invitrogen) present in the defined medium, and could be
differentiated appropriately. Fig. 6A shows an Oct4
+ hESC colony
cultured in this completely xeno-free defined medium for 7
passages. Similar to ESCs cultured in ESC defined medium with
BSA, NSCs could be effectively generated from ESCs adapted to
this completely xeno-free medium (Fig. 6B–C). Moreover, these
NSCs retained the capacity to differentiate into dopaminergic
neuronswhen exposureto PA6-CM or Shhand FGF8(Fig. 6D). No
apparent differences were found between NSCs generated under
this xeno-free condition and the defined conditions described above
in terms of dopaminergic differentiation efficiency. These results
suggest that NSCs and dopaminergic neurons can be generated
under xeno-free defined conditions from hESCs adapted to xeno-
Table 1. Genes highly expressed in dopaminergic neurons by
microarray analysis.
Markers Gene name NSCs D32 D32/NSCs
NSC SOX1 39 1 0.03
NES 3509 2501 0.71
PAX6 530 197 0.37
huD 55 1465 26.64
Dopaminergic pathway EN1 19 43 2.26
EN2 281 16 0.06
OTX2 1 82 82.00
PAX2 3 97 32.33
MSX1 40 152 3.80
LMX1A 1 48 48.00
NEUROG2 324 505 1.56
FOXA2 1 94 94.00
GLI3 1299 82 0.06
DVL3 1334 450 0.34
SFRP2 9352 285 0.03
TH 11 700 63.64
DDC 39 87 2.23
SMO 890 108 0.12
KCNJ6 6 797 132.83
Nurr1 9 107 11.89
SRGAP3 277 6425 23.19
RET 9 36 4.00
FGF20 9 44 4.89
doi:10.1371/journal.pone.0006233.t001
Figure 4. Four-step differention into midbrain dopaminergic neurons in a completely defined medium. (A) A schematic diagram of the
four-step (ESCRpropagation and storage of NSCRinduction of a midbrain dopaminergic precursor populationRmaturation of the precursor to
dopaminergic neurons) differentiation protocol for generation of dopaminergic neurons in completely defined media. (B–D) Defined medium
adapted NSCs differentiated into dopaminergic neurons in defined media.
doi:10.1371/journal.pone.0006233.g004
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clinical applications of hESC-derived cells.
Generation of dopaminergic neurons using hESC derived
in defined, nearly xeno-free, conditions
We have previously shown that hESCs can be maintained in
defined conditions for prolonged time periods while retaining their
pluripotency, and our current experiments suggested that each of the
remaining steps could utilize such a line to generate dopaminergic
neurons. We reasoned that a new line isolated without exposure to
xeno components could be used in such a differentiation process with
our defined medium protocols, and that this line could generate
clinically useful differentiated cell populations. We therefore tested a
hESC line (W10) that was derived under serum- and nearly xeno-free
conditions [30]. As seen in Fig. 7, nestin-expressing NSCs could be
generated from W10 cells cultured in defined medium and these
NSCs could be differentiated into TH
+ dopaminergic neurons in a
similar manner as the I6-derived NSCs.
Discussion
In this manuscript we describe a process that is readily scalable
for production of functional dopaminergic neurons from hESCs
Figure 5. NSCs differentiated into functional dopaminergic neurons in vivo. Day 20 cells (after the NSC stage) were transplanted into the
striatum of rats. Differentiation and survival of donor-derived dopaminergic neurons are seen in striatum two (A–D) and seven (E–H) weeks post of
transplantation. Transplantation of day 20 cells in 6-OHDA rats showed a subset of human dopaminergic neurons, which survived eight weeks post of
graft (I–L). Rotary tests showed amelioration of behavioral deficits in PD rats transplanted with donor-derived dopaminergic neurons (M).
doi:10.1371/journal.pone.0006233.g005
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transferred to a GMP facility that could generate a qualified
product for clinical use. The process can be broken into four steps:
1) derivation and propagation of ESC, 2) propagation and storage
of NSC, 3) induction of a midbrain dopaminergic precursor
population, and 4) maturation of the precursor to dopaminergic
neurons. Our data suggest that each step could utilize xeno-free
defined media that are suitable for scalable GMP manufacture of
cells for clinical use. Neurons generated by this process appear to
be authentic A9 dopaminergic neurons as assessed by in vitro
(expression of midbrain dopaminergic markers) and in vivo (ability
to survive after transplantation) assays.
Although it is not necessary to exclude xeno components in the
culture and differentiation of hESCs for clinical applications,
provided appropriate validation tests are performed, we believe
that xeno components should be avoided as much as possible,
Figure 6. Completely serum- and xeno-free defined culturing of hESCs and NSCs. Morphology and expression of Oct4 (A) in hESCs that
were cultured in xeno-free medium (hKSR with growth factors) for 7 passages. NSCs derived from xeno-free cultured hESCs expressed nestin and
Sox1 (B–C) and could differentiate into dopaminergic neurons (D).
doi:10.1371/journal.pone.0006233.g006
Figure 7. Generation of dopaminergic neurons from serum-free derived hESCs. NSCs could be generated from hESC line derived under
serum-free and minimal xeno component exposure conditions as efficient as from defined medium adapted hESCs. Expression of nestin in NSCs (A)
and differentiation into dopaminergic neurons (B).
doi:10.1371/journal.pone.0006233.g007
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medical use [31]. Analyzing the components in our defined
medium preparations, we identified three major sources of xeno
material: BSA as a component of various media formulations,
geltrex (which was used as a substrate in several stages of the
process) and PA6-CM. In addition, there was the potential of
exposure to xeno components as part of the hESC derivation
process. We showed that hKSR (in completely humanized base
medium with growth factors) could replace BSA and serum
containing medium, and that a defined substrate - fibronectin
(CellStart) - could substitute for geltrex in the culture of hESCs
and hESC-derived NSC, and the process of inducing NSCs.
Likewise, Shh and FGF8 could substitute for PA6-CM in the
induction process and BDNF and GDNF along with TGFb could
substitute for the maintenance and survival effect of PA6-CM.
One advantage of our process of generating dopaminergic
neurons from hESCs is the potential for scalability. As shown in the
results, NSCs derived from defined cultured hESCs could be frozen
and thawed, and NSCs cultured for prolonged periods retain the
ability to differentiate into authentic A9 dopaminergic neurons both
in vitroand invivo. Theefficiency ofdopaminergic differentiation is
sufficient for scalable production, as a high percentage of
dopaminergic neurons can be obtained without enrichment.
A process amendable for GMP manufacture does not simply
require the development of components, but also replicable tests to
establish the quality of the end product. Toward this end, we have
employed a large-scale microarray analysis and identified a panel
of stage-specific markers that could be used to rapidly assess the
quality of the end product. These include markers of NSCs,
dopaminergic precursors and mature dopaminergic neurons,
expression of which could be reliably assessed by real time PCR
and/or immunocytochemistry.
Although the protocol we described works with multiple hESC
lines, and we and others have shown that multiple lines can be
adapted to serum free conditions, we acknowledge that we have
not yet successfully derived a line in completely xeno-free defined
conditions and shown that we can successfully generate dopami-
nergic neurons using this process. As an interim measure we have
adapted a hESC line derived under nearly xeno-free condition
[30] to defined medium conditions using CellStart as a substrate at
an early passage culture. We show that such an adapted line can
be readily differentiated into dopaminergic neurons using our
four-step protocol and the defined media and growth factors
described. We believe that these results suggest that it will be
possible to derive cell lines in hKSR on a defined substrate and
that such lines will be similar to other hESC lines and will
differentiate into dopaminergic neurons following this protocol.
We note as well that we have used growth factors and
components that were themselves not manufactured under GMP
protocols as would be required for a true GMP process, nor was this
process tested in a GMP facility. In addition, we have not
demonstrated a GMP-applicable process for purifying dopaminer-
gic neuron cultures. There were several reasons why we did not
undertake these efforts even though we believe that these are easily
solvable problems. One important reason was cost, as developing
GMP grade material such as antibodies and growth factors would
be required prior to finalizing a protocol. Thesecond was the lack of
access to a GMP facility that had the requisite expertise in adherent
cell culture and dopaminergic neuron differentiation, and the
absence of consensus on what degree of purification (if any) is
required for a final product. We have however initiated preliminary
discussions with commercial providers who have assured us that
such products can be developed when they are required.
In summary, we have shown that hESCs and NSCs can be
maintained in xeno-free defined media for a prolonged period of
time while retaining their ability to differentiate into authentic
dopaminergic neurons. Our defined medium system provides a
path to a scalable GMP-applicable process of generation of
dopaminergic neurons from hESCs for therapeutic applications,
and a ready source of large numbers of neurons for potential
screening applications.
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